209 related articles for article (PubMed ID: 16971805)
21. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
22. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.
Kawai S; Yoshimura Y; Iida S; Kinoshita Y; Koishihara Y; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Oncol Rep; 2006 Feb; 15(2):361-7. PubMed ID: 16391855
[TBL] [Abstract][Full Text] [Related]
24. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
25. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
27. A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model.
Sato F; Ito A; Ishida T; Mori F; Takino H; Inagaki A; Ri M; Kusumoto S; Komatsu H; Iida S; Okada N; Inagaki H; Ueda R
Cancer Immunol Immunother; 2010 Dec; 59(12):1791-800. PubMed ID: 20714721
[TBL] [Abstract][Full Text] [Related]
28. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
Carlo-Stella C; Di Nicola M; Turco MC; Cleris L; Lavazza C; Longoni P; Milanesi M; Magni M; Ammirante M; Leone A; Nagy Z; Gioffrè WR; Formelli F; Gianni AM
Cancer Res; 2006 Feb; 66(3):1799-808. PubMed ID: 16452241
[TBL] [Abstract][Full Text] [Related]
29. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines.
Huang YW; Burrows FJ; Vitetta ES
Hybridoma; 1993 Dec; 12(6):661-75. PubMed ID: 7904588
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
33. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma.
Kikuchi Y; Uno S; Kinoshita Y; Yoshimura Y; Iida S; Wakahara Y; Tsuchiya M; Yamada-Okabe H; Fukushima N
Leuk Res; 2005 Apr; 29(4):445-50. PubMed ID: 15725479
[TBL] [Abstract][Full Text] [Related]
35. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
Green SK; Karlsson MC; Ravetch JV; Kerbel RS
Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model.
Boehncke WH; Ochsendorf FR; Noll S; Urban M; Popp A; Waldherr D; Haunschild J; Litzenburger T
Br J Dermatol; 2005 Oct; 153(4):758-66. PubMed ID: 16181457
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.
Leoh LS; Kim YK; Candelaria PV; Martínez-Maza O; Daniels-Wells TR; Penichet ML
J Immunol; 2018 May; 200(10):3485-3494. PubMed ID: 29654211
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
[TBL] [Abstract][Full Text] [Related]
40. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
Francisco JA; Donaldson KL; Chace D; Siegall CB; Wahl AF
Cancer Res; 2000 Jun; 60(12):3225-31. PubMed ID: 10866315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]